01 / DESIGN
What was studied?
An enzyme assay and modeling compared BPC-157 with two designed hybrid peptides for acetylcholinesterase inhibition.
02 / FINDINGS
What did the researchers report?
The peptides showed competitive inhibition, with the modified analogs performing differently. Potency was substantially lower than that of established clinical inhibitors.
03 / LIMITS
How should it be interpreted?
An enzyme interaction does not demonstrate neurological benefit. Hybrid sequences are distinct molecules, and results do not support treating a catalog peptide as an Alzheimer therapy.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.